精子数カウント検査市場：世界の産業規模、動向、機会、予測、技術別、エンドユーザー別、地域別、競合、2019年～2029年

精子数カウント検査の世界市場規模は、2023年に21億3,000万米ドルとなり、2029年までの予測期間のCAGRは6.52%で、着実な成長が予測されています。

精子数カウント検査は、男性の精液と精子の特定の特性を評価するために研究所で実施される診断手順です。主に、受精に必要な精子の正常性と生存能力を判定することにより、男性の生殖能力を評価するために利用されます。分析中に検査される主なパラメータには、精子数（精液1mlあたりの精子の濃度）、精子の運動率（効果的に動く能力）、精子の形態（大きさや形）、精液量、pHレベル、異常や感染の有無などがあります。乏精子症として知られる精子数の少なさ、精子の形態異常、運動率の悪さは受精の妨げになります。

自動精液分析システム、分子診断、デジタル・ソリューションの最近の進歩により、これらの検査の精度と効率が大幅に向上しています。サービスは通常、不妊治療専門クリニック、病院、診断研究所が提供しています。また、遠隔医療ソリューションや、男性が自宅で精液サンプルを採取し、ラボに送って評価を受けることができる消費者直接検査キットへの動向も高まっています。これらのキットは便利ではあるが、臨床現場で得られるような包括的な分析はできないかもしれないです。

精子数カウント検査市場は、不妊率の増加、診断技術の進歩、男性不妊検査・治療に対する社会的意識の変化により拡大しています。しかし、検査の精度を確保し、世界的に多様な規制の枠組みをうまく乗り切るという課題は依然として残っています。こうした課題にもかかわらず、現在進行中の技術革新と消費者の意識の高まりは、この分野の将来が有望であることを示唆しています。

市場促進要因

男性不妊率の増加

生殖補助技術に対する需要の高まり

主な市場課題

正確性と標準化

社会的スティグマ

主な市場動向

技術の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界の精子数カウント検査市場に与える影響

第5章 世界の精子数カウント検査市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別（顕微鏡、クロマトグラフィー免疫測定法および比色反応、スマートフォンベース、その他）
  • エンドユーザー別（病院、不妊治療センター、その他）
  • 地域別
  • 企業別（2023）
• 市場マップ

第6章 アジア太平洋地域の精子数カウント検査市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別
  • エンドユーザー別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州の精子数カウント検査市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別
  • エンドユーザー別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米の精子数カウント検査市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別
  • エンドユーザー別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米の精子数カウント検査市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの精子数カウント検査市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別
  • エンドユーザー別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • UAE

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の精子数カウント検査市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• DNA Diagnostics Center, Inc.
• Financials（As Reported）
• Recent Developments
• BioMerieux SA
• Medical Electronic Systems
• Thermo Fisher Scientific Inc.
• CooperSurgical, Inc.
• Vitrolife Sweden AB
• Hamilton Thorne Inc.
• Artron Laboratories Inc.
• Fertility Focus Ltd.
• MICROPTIC S.L.

第16章 戦略的提言

第17章 調査会社について・免責事項

Global Sperm Count Test Market was valued at USD 2.13 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 6.52% through 2029. A sperm count test is a diagnostic procedure conducted in laboratories to assess specific characteristics of semen and sperm in men. It is primarily utilized to evaluate male fertility by determining the normality and viability of sperm for fertilization. Key parameters examined during the analysis include sperm count (the concentration of sperm per milliliter of semen), sperm motility (their ability to move effectively), sperm morphology (their size and shape), semen volume, pH levels, and the presence of abnormalities or infections. This test is crucial as it directly impacts fertility; low sperm count known as oligospermia, abnormal sperm morphology, or poor motility can hinder fertilization.

Recent advancements in automated semen analysis systems, molecular diagnostics, and digital solutions have significantly enhanced the accuracy and efficiency of these tests. Services are typically offered by specialized fertility clinics, hospitals, and diagnostic laboratories. There is also a growing trend towards telemedicine solutions and direct-to-consumer testing kits, which allow men to collect semen samples at home and send them to labs for evaluation. While convenient, these kits may not provide the comprehensive analysis available in clinical settings.

The market for sperm count tests is expanding due to increasing infertility rates, advancements in diagnostic technologies, and changing societal attitudes towards male fertility testing and treatment. However, challenges persist in ensuring test accuracy and navigating diverse regulatory frameworks globally. Despite these challenges, ongoing innovations and heightened consumer awareness suggest a promising future for this field.

Key Market Drivers

Increasing Male Infertility Rates

As male infertility rates increase worldwide, there is a corresponding surge in demand for diagnostic services aimed at identifying the underlying causes of infertility. Sperm count tests are pivotal in evaluating male infertility by assessing sperm quantity, quality, and motility. According to the Hudson Institute of Medical Research, male infertility often stems from issues related to sperm production or delivery to the egg. Approximately one in 20 men experience low sperm counts, which can lead to infertility, while about one in 100 men may have no sperm count at all.

Growing awareness among men about infertility issues is prompting more individuals to seek medical consultation and undergo fertility assessments, including sperm count tests. This heightened awareness contributes to an expanding clientele for sperm count testing services. The results of sperm count tests significantly influence treatment decisions for male infertility. Depending on the severity of the condition, such as low sperm count or poor sperm motility, healthcare providers may recommend various interventions, including lifestyle adjustments, medications, or assisted reproductive technologies (ART). Accurate sperm count assessments are essential for determining the appropriate course of treatment. A report by Yale Medicine indicates that roughly 15 percent of couples in the United States experience difficulties conceiving, with male infertility issues identified in over 50 percent of cases.

Advancements in diagnostic technologies have notably improved the precision and efficiency of sperm count tests, enhancing their accessibility and reliability. These advancements appeal to both healthcare professionals and consumers, driving expansion within the market. The rising prevalence of male infertility not only underscores the growing demand for sperm count tests but also stimulates innovation, investment, and market growth within the global sperm count test market.

Rising Demand for Assisted Reproductive Technologies

Assisted reproductive technologies (ART) such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) heavily rely on the quality and quantity of sperm. Sperm count tests are crucial for assessing sperm viability, motility, and morphology, providing essential data for ART procedures. Globally, there is increasing acceptance and adoption of ART due to rising infertility rates, changing societal norms, and couples delaying parenthood. According to the Center for Disease Control and Prevention (CDC), the use of ART procedures has doubled over the past decade, with approximately 1.9% of infants born annually resulting from IVF. This growing preference for ART to achieve pregnancy escalates the demand for accurate sperm count tests to ensure the effectiveness of these procedures.

Sperm count tests enable fertility specialists to diagnose male infertility conditions accurately. Depending on the results such as low sperm count or poor motility, Healthcare providers can tailor treatment plans that may include lifestyle adjustments, medications, or specific ART methods.

Continuous research efforts aimed at enhancing understanding of male infertility and developing advanced diagnostic technologies further propel market expansion. Innovations in sperm analysis methods continually refine diagnostic accuracy and expand the capabilities of fertility clinics worldwide. This trend underscores the critical role of sperm count tests in facilitating effective fertility treatments and underscores the market's growth potential in an evolving healthcare landscape.

Key Market Challenges

Accuracy and Standardization

Different laboratories and clinics employ varying methodologies for conducting sperm count tests, which can lead to inconsistent results and interpretations, impacting the reliability and comparability of diagnostic outcomes. Accurate calibration of equipment used in these tests, such as microscopes and automated semen analysis systems, is critical to ensure precise measurements. Any deviations in calibration procedures can introduce errors that affect the accuracy of test results.

Variability in testing protocols and quality assurance practices among different laboratories contributes to disparities in sperm count results obtained from different facilities, undermining confidence in the accuracy of these outcomes. While technological advancements enhance the accuracy and efficiency of sperm count tests, integrating new technologies into routine clinical practice requires rigorous validation and standardization across various healthcare settings. Ensuring the compatibility and reliability of these innovations with existing methodologies is essential for maintaining consistent diagnostic standards. The regulatory landscape related to the validation and standardization of diagnostic tests varies globally, adding complexity and cost for market participants, particularly international manufacturers and providers. Establishing and adhering to standardized testing protocols, strengthening quality assurance measures, and promoting education and training on best practices in sperm count testing are crucial steps toward advancing the accuracy and reliability of diagnostic services in evaluating male infertility.

Societal Stigma

There is a persistent stigma surrounding fertility issues, including male infertility, which discourages men from discussing or seeking help for reproductive health concerns, including fertility testing. This stigma often leads to delayed diagnosis and treatment, impacting the demand for sperm count tests in the market. Psychological barriers, such as embarrassment or fear of judgment, frequently deter men from undergoing necessary tests, even when recommended, thereby hindering market growth.

In some cultures, conversations about fertility and reproductive health are taboo or primarily seen as the domain of women, resulting in minimal focus on male fertility testing and treatment. Low awareness and limited dialogue about fertility issues further complicate efforts to promote men's health and normalize fertility testing. To address these challenges and expand the global market for sperm count tests, it is crucial to launch educational campaigns, advocacy initiatives, and initiatives that foster open dialogue on reproductive health. Increasing awareness and encouraging open discussions can help reduce stigma, improve access to fertility testing, and ultimately support better reproductive health outcomes for men worldwide.

Key Market Trends

Technological advancements

Advancements in diagnostic technologies, such as automated semen analysis systems and digital imaging, enhance the precision and accuracy of sperm count tests, providing more dependable results critical for diagnosing male infertility and guiding treatment decisions. Researchers at Sao Paulo State University have successfully employed flow cytometry for functional analysis of human sperm, adapting techniques originally used to study bovine reproductive cells. This study utilized a cytometer equipped with lasers to excite fluorophores and filters to detect fluorescence, enabling simultaneous observation of various characteristics of human sperm related to fertility.

Continuous research and development efforts introduce innovative testing methods that enhance the sensitivity and specificity of sperm count assessments. Integration of data analytics and artificial intelligence (AI) algorithms in sperm count testing aids in pattern recognition, predictive analysis, and personalized treatment recommendations. For instance, in 2023, Australian experts demonstrated the effectiveness of an AI tool called SpermSearch in rapidly analyzing sperm viability for intracytoplasmic sperm injection (ICSI), surpassing human experts in accuracy. This study was presented at the annual meeting of the European Society of Human Reproduction and Embryology in Copenhagen, Denmark.

Technological advancements facilitate the integration of sperm count testing with telemedicine platforms, allowing for remote consultations, virtual result interpretations, and seamless communication between patients and healthcare providers. ExSeed Health's development of a male home fertility test, endorsed by the Agora Clinic in Brighton, exemplifies these innovations. Additionally, a 2023 study from the University of California, Los Angeles (UCLA) suggests a potential link between the health of the semen microbiome and male infertility, identifying microorganisms that may affect sperm motility and fertility. These advancements drive market growth by addressing evolving healthcare needs, enhancing patient outcomes, and broadening the adoption of fertility diagnostics worldwide.

Segmental Insights

Technique Insights

Based on Technique, the Smartphone-based emerged as the fastest growing segment in the global market for Sperm Count Test during forecast period. This is driven by its accessibility, convenience, user-friendly interface, privacy features, technological integration, and cost-effectiveness. These kits are designed with intuitive interfaces and straightforward instructions, ensuring they are accessible to a diverse user base. Performing sperm count tests in the privacy of one's home addresses concerns about privacy and stigma associated with fertility testing, appealing particularly to those uncomfortable discussing reproductive health in clinical settings. Smartphone-based tests deliver rapid results, enabling users to promptly receive feedback on sperm count and other parameters, facilitating quick decisions on further medical consultations or lifestyle adjustments. The growth of smartphone-based testing mirrors broader trends in consumer empowerment in healthcare and the adoption of digital health solutions. Increasing awareness and acceptance of telemedicine and digital diagnostics contribute significantly to the expanding market presence of smartphone-based sperm count tests.

End User Insights

Based on End User, the Fertility Centers emerged as emerged as the dominating segment in the global market for Sperm Count Test in 2023. Fertility centers lead in the global sperm count market due to their specialized expertise, extensive service offerings, advanced technology, patient-focused care, research efforts, collaborative partnerships, and strong consumer confidence. These centers are staffed by highly trained reproductive endocrinologists, fertility specialists, and embryologists who specialize in diagnosing and treating infertility, including comprehensive male fertility assessments such as sperm count testing. In the United States alone, there are approximately 456 in-vitro fertilization centers dedicated to infertility treatment, according to the Centers for Disease Control and Prevention (CDC). Fertility centers invest in cutting-edge diagnostic equipment and technologies tailored for fertility assessments, such as automated semen analysis systems, digital imaging, and molecular diagnostics, which significantly enhance the precision and dependability of sperm count tests. Moreover, these centers maintain extensive networks and collaborate closely with various healthcare providers, including urologists, genetic counselors, and psychologists, enabling them to offer integrated evaluations and cohesive care plans for patients dealing with complex fertility challenges. Collectively, these attributes establish fertility centers as the preferred choice for individuals and couples worldwide seeking comprehensive fertility evaluations and treatments.

Regional Insights

Based on Region, North America emerged as the dominant region in the Global Sperm Count Test Market in 2023. North America's dominance in the global sperm count test market stems from its advanced healthcare infrastructure, widespread awareness and acceptance of fertility treatments, technological advancements, stringent regulatory oversight, research initiatives, and favorable insurance coverage. The region is home to leading research institutions and universities conducting pioneering research in reproductive medicine and infertility. This ongoing research drives innovations in fertility diagnostics and treatments, enhancing the capabilities of fertility centers across North America. For instance, in 2024, Wayne State University School of Medicine received a $3.4 million award from the National Institutes of Health to explore mitochondrial DNA levels in sperm as a novel biomarker for sperm fitness and predictive of couples' reproductive success. Healthcare plans in North America, particularly in the United States, often include coverage for fertility treatments, such as sperm count tests and assisted reproductive technologies (ART), which reduces financial barriers for patients and increases accessibility to fertility services. The region also benefits from a cultural environment that promotes open discussions about reproductive health, fostering a supportive atmosphere that encourages individuals and couples to seek fertility evaluations and treatments. The supportive infrastructure facilitates the operation of robust fertility clinics and centers equipped to provide comprehensive sperm count testing and infertility treatments.

Key Market Players

DNA Diagnostics Center, Inc.

BioMerieux SA

Medical Electronic Systems

Thermo Fisher Scientific Inc.

CooperSurgical, Inc.

Vitrolife Sweden AB

Hamilton Thorne Inc.

Artron Laboratories Inc.

Fertility Focus Ltd.

MICROPTIC S.L.

Report Scope:

In this report, the Global Sperm Count Test Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Sperm Count Test Market, By Technique:

Microscopy Chromatographic Immunoassay and Colorimetric Reaction Smartphone-based Others

Sperm Count Test Market, By End User:

Hospitals Fertility Centers Others

Sperm Count Test Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Sperm Count Test Market.

Available Customizations:

Global Sperm Count Test Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Impact of COVID-19 on Global Sperm Count Test Market

5. Global Sperm Count Test Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technique (Microscopy, Chromatographic Immunoassay and Colorimetric Reaction, Smartphone-based, Others)
  • 5.2.2. By End User (Hospitals, Fertility Centers, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2023)
• 5.3. Market Map

6. Asia Pacific Sperm Count Test Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technique
  • 6.2.2. By End User
  • 6.2.3. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Sperm Count Test Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technique
      • 6.3.1.2.2. By End User
  • 6.3.2. India Sperm Count Test Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technique
      • 6.3.2.2.2. By End User
  • 6.3.3. Australia Sperm Count Test Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technique
      • 6.3.3.2.2. By End User
  • 6.3.4. Japan Sperm Count Test Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Technique
      • 6.3.4.2.2. By End User
  • 6.3.5. South Korea Sperm Count Test Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Technique
      • 6.3.5.2.2. By End User

7. Europe Sperm Count Test Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technique
  • 7.2.2. By End User
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Sperm Count Test Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technique
      • 7.3.1.2.2. By End User
  • 7.3.2. Germany Sperm Count Test Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technique
      • 7.3.2.2.2. By End User
  • 7.3.3. Spain Sperm Count Test Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technique
      • 7.3.3.2.2. By End User
  • 7.3.4. Italy Sperm Count Test Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technique
      • 7.3.4.2.2. By End User
  • 7.3.5. United Kingdom Sperm Count Test Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technique
      • 7.3.5.2.2. By End User

8. North America Sperm Count Test Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technique
  • 8.2.2. By End User
  • 8.2.3. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Sperm Count Test Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technique
      • 8.3.1.2.2. By End User
  • 8.3.2. Mexico Sperm Count Test Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technique
      • 8.3.2.2.2. By End User
  • 8.3.3. Canada Sperm Count Test Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technique
      • 8.3.3.2.2. By End User

9. South America Sperm Count Test Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technique
  • 9.2.2. By End User
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Sperm Count Test Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technique
      • 9.3.1.2.2. By End User
  • 9.3.2. Argentina Sperm Count Test Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technique
      • 9.3.2.2.2. By End User
  • 9.3.3. Colombia Sperm Count Test Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technique
      • 9.3.3.2.2. By End User

10. Middle East and Africa Sperm Count Test Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technique
  • 10.2.2. By End User
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Sperm Count Test Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technique
      • 10.3.1.2.2. By End User
  • 10.3.2. Saudi Arabia Sperm Count Test Market Outlook
    • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technique
      • 10.3.2.2.2. By End User
  • 10.3.3. UAE Sperm Count Test Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technique
      • 10.3.3.2.2. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Sperm Count Test Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. DNA Diagnostics Center, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
• 15.4. Financials (As Reported)
• 15.5. Recent Developments
• 15.2. BioMerieux SA
• 15.3. Medical Electronic Systems
• 15.4. Thermo Fisher Scientific Inc.
• 15.5. CooperSurgical, Inc.
• 15.6. Vitrolife Sweden AB
• 15.7. Hamilton Thorne Inc.
• 15.8. Artron Laboratories Inc.
• 15.9. Fertility Focus Ltd.
• 15.10. MICROPTIC S.L.

16. Strategic Recommendations

17. About Us & Disclaimer